Opthea Limited (OPTEY) - Net Assets
Based on the latest financial reports, Opthea Limited (OPTEY) has net assets worth $-168.71 Million USD as of December 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($145.77 Million) and total liabilities ($314.48 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Opthea Limited (OPTEY) financial obligations for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-168.71 Million |
| % of Total Assets | -115.73% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Opthea Limited - Net Assets Trend (2022–2025)
This chart illustrates how Opthea Limited's net assets have evolved over time, based on quarterly financial data. Also explore OPTEY total assets for the complete picture of this company's asset base.
Annual Net Assets for Opthea Limited (2022–2025)
The table below shows the annual net assets of Opthea Limited from 2022 to 2025. For live valuation and market cap data, see OPTEY company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $-201.07 Million | -165.23% |
| 2024-06-30 | $-75.81 Million | -1195.19% |
| 2023-06-30 | $-5.85 Million | -112.20% |
| 2022-06-30 | $47.98 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Opthea Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 52555364700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $541.43 Million | % |
| Total Equity | $-201.07 Million | 100.00% |
Opthea Limited Competitors by Market Cap
The table below lists competitors of Opthea Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
WEBUY GLOBAL LTD. Ordinary Shares
NASDAQ:WBUY
|
$3.42 Million |
|
St James Gold Corp
V:LORD
|
$3.42 Million |
|
Stelar Metals Ltd
AU:SLB
|
$3.43 Million |
|
REGENER8 Resources NL
AU:R8R
|
$3.43 Million |
|
Libas Consumer Products Limited
NSE:LIBAS
|
$3.42 Million |
|
FIRST CLASS MET. LS-001
F:WN9
|
$3.42 Million |
|
Hochdorf Holding AG
SW:HOCN
|
$3.41 Million |
|
Poddar Housing and Development Limited
NSE:PODDARHOUS
|
$3.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Opthea Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -75,810,000 to -201,069,000, a change of -125,259,000.
- Net loss of 162,791,000 reduced equity.
- New share issuances of 34,809,000 increased equity.
- Other factors increased equity by 2,723,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-162.79 Million | -80.96% |
| Share Issuances | $34.81 Million | +17.31% |
| Other Changes | $2.72 Million | +1.35% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Opthea Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-06-30 | $0.12 | $0.02 | x |
| 2023-06-30 | $-0.01 | $0.02 | x |
| 2024-06-30 | $-0.07 | $0.02 | x |
| 2025-06-30 | $-0.16 | $0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Opthea Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -651164.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-48.37%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -193.46% | -102353.66% | 0.00x | 1.25x | $-97.62 Million |
| 2023 | 0.00% | -131963.89% | 0.00x | 0.00x | $-141.94 Million |
| 2024 | 0.00% | -176193.60% | 0.00x | 0.00x | $-212.66 Million |
| 2025 | 0.00% | -651164.00% | 0.00x | 0.00x | $-142.68 Million |
Industry Comparison
This section compares Opthea Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Opthea Limited (OPTEY) | $-168.71 Million | -193.46% | N/A | $3.42 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Opthea Limited
Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME).… Read more